SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

KarXT

ZLAB·Zai Lab Ltd
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available in both the US (since September 2024) and China (since June 2026).
Why 4/10
KarXT is already approved in both the US (by BMS) and China (by Zai Lab). No hard, dated binary catalyst (PDUFA, pivotal readout, AdComm) remains for this drug in the next ~12 months for Zai Lab. The defining binary events have passed; the focus is on commercial ramp and NRDL negotiation, which are gradual, not binary. ImpactScore defaults to 4 for an approved, commercial-stage drug with no pending regulatory decision.
Actionable Insight NEUTRAL

KarXT is already approved and launching in China, so the next stock-moving events for Zai Lab around this drug are commercial milestones: NRDL (national reimbursement) negotiation outcomes, quarterly sales growth trends, and any label expansion for Alzheimer's psychosis or bipolar mania that Zai Lab might pursue in China. The next major binary catalyst for Zai Lab overall is the November 30, 2026 PDUFA date for povetacicept in IgAN, not KarXT.

Price Chart

Loading chart...

Executive Summary

KarXT (xanomeline/trospium chloride), sold as Cobenfy in the US and as Karigel/Kaigele in China, is a first-in-class oral medication for schizophrenia that works through muscarinic receptors rather than the traditional dopamine-blocking pathway. Developed by Karuna Therapeutics (acquired by Bristol-Myers Squibb for $14 billion), it was FDA-approved in the US in September 2024. Zai Lab (ZLAB) holds exclusive rights for Greater China under a 2021 licensing deal. China's NMPA approved KarXT in December 2025, and Zai Lab commercially launched it in mainland China in June 2026. For Zai Lab investors, the defining binary catalysts (US FDA approval, China NMPA approval) have already passed; the focus now is on commercial execution, NRDL reimbursement negotiation, and revenue contribution alongside Zai Lab's broader pipeline.

How It Works

KarXT is a combination of two drugs in one pill. Xanomeline activates muscarinic receptors (M1/M4) in the brain to improve schizophrenia symptoms, while trospium chloride blocks those same receptors in the rest of the body to reduce side effects like nausea and vomiting. This is the first schizophrenia drug in decades that works through this muscarinic pathway instead of blocking dopamine receptors.

Trial Status

FDA approved in the US (September 2024) and NMPA approved in China (December 2025). Commercially launched in mainland China in June 2026. Phase 3 trials for bipolar mania (BALSAM-2) and Alzheimer's disease psychosis (ADEPT program) are ongoing globally, led by Bristol-Myers Squibb. Zai Lab is conducting a real-world study in Chinese schizophrenia patients.

The Two-Sided Case

▲ Bull Case4
First-in-class mechanism: KarXT is the first schizophrenia drug with a novel mechanism in over 50 years, addressing a massive unmet need across 8 million+ patients in China alone.
Approved and launching: NMPA approval secured in December 2025 and commercial launch in China began June 2026, with early launch trends described as encouraging by management.
Strong institutional accumulation: Multiple tracked managers (FMR LLC, Goldman Sachs, Woodline Partners) doubled or initiated positions in Zai Lab during Q2 2026, signaling confidence in the commercial opportunity.
Analyst consensus is bullish: 10 of 13 analysts rate Zai Lab Buy or Strong Buy, with a mean price target of $33.48 versus the recent price around $22.60, implying roughly 48% upside.
▼ Bear Case5
No near-term binary catalyst: With both US and China approvals secured, there is no upcoming PDUFA or pivotal readout for KarXT to drive a sharp re-rating for Zai Lab.
Commercial execution risk: KarXT is a new entrant in China's schizophrenia market; NRDL reimbursement inclusion is not guaranteed and pricing negotiations could pressure margins.
Insider selling: CFO Chen Yajing and director Lis William sold shares in August 2026 (some under 10b5-1 plans), which may signal limited near-term upside conviction from insiders.
Zai Lab is a multi-product company: KarXT is just one of several products (ZEJULA, VYVGART, NUZYRA, OPTUNE, TIVDAK, povetacicept), so KarXT's individual contribution to the stock is diluted across the pipeline.
Competition ahead: AbbVie and other companies are developing next-generation schizophrenia drugs with similar muscarinic mechanisms that could eventually compete with KarXT.

Upcoming Catalysts

  • NRDL (National Reimbursement Drug List) negotiation outcome for KarXT in China - timing uncertain but typically annual cycle.
  • Quarterly sales growth trajectory for KarXT in China (next earnings likely early 2027 for Q4 2026).
  • BMS-led Phase 3 readouts for KarXT in bipolar mania and Alzheimer's psychosis - these are global trials, not Zai Lab-specific, but positive data could support future China label expansion.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Zai Lab Ltd 8-K ZLAB ·Originating report

Sources · 12

Hover a chip for the title
1 biospace.com2 zailaboratory.com3 nasdaq.com4 biospace.com5 pharmaphorum.com6 media.drugdu.com7 sipac.gov.cn8 fiercepharma.com9 en.wikipedia.org10 news.bms.com11 psychiatrictimes.com12 fool.com